NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

骨髓發育異常症候群(MDS)治療的全球市場:2020-2027

Global Myelodysplastic Syndrome (MDS) Treatment Market - 2020-2027

出版商 DataM Intelligence 商品編碼 962190
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
骨髓發育異常症候群(MDS)治療的全球市場:2020-2027 Global Myelodysplastic Syndrome (MDS) Treatment Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

骨髓發育異常症候群(MDS),也稱為 "骨髓營養不良症" ,是一種骨髓病,可阻止骨髓產生足夠的健康血細胞。它沒有造血功能。它在老年人中更常見,在男性中比在女性中更常見。

MDS的特徵在於JAK激□中特定的染色體突變,例如多條染色體q肢的缺失,5號或7號染色體的缺失以及8號染色體的額外副本。外周血塗片,顯微鏡檢查,細胞化學,流式細胞儀,免疫療法,細胞遺傳學,FISH,PCR等用於診斷MDS。

促進MDS治療市場擴大的因素包括老年人口的增加,認識的提高,新治療方法的出現,政府為實現有針對性的治療方法而做出的努力以及有利的補償政策。可以提到。 MDS是最常見的惡性血液病之一,發生在100,000人中的4.8人中,在美國每年有13,000多個新病例發生。由於管道藥品,藥品批准以及新藥開發的研發投資的增加,MDS治療市場預計將繼續穩定增長。

本報告調查了全球MDS藥物市場,並提供了有關市場動態,行業分析,治療方法,最終用戶,區域分析,競爭狀況,公司概況等信息。

目錄

第1章調查方法和範圍

第2章市場定義和概述

第3章執行摘要

第4章市場動態

  • 影響市場的因素
    • 促進因素
    • 抑制因素
    • 市場機會
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 未滿足的需求
  • COVID-19的影響分析

第6章,按待遇劃分的市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 幹細胞移植*
    • 免疫療法
    • 化學療法
    • 增殖因子
    • 其他

第7章最終用戶的市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 醫院*
    • 專科診所
    • 其他

第8章區域市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲

第9章競爭情況

  • 競爭情景
  • 市場定位/佔有率分析
  • 併購分析

第10章公司簡介

  • Otsuka America Pharmaceutical Inc.*
  • AbbVie
  • Accord Healthcare Ltd.
  • Novartis
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company Limited
  • Onconova Therapeutics
  • Celgene Corporation
  • Sandoz, Inc.
  • Dr. Reddy's Laboratories, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Argenx
  • Jazz Pharmaceuticals Inc.

第11章主要調查結果

第12章全球骨髓營養不良綜合徵(MDS)治療市場

目錄

Market Overview

The global myelodysplastic syndrome (MDS) treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Myelodysplastic Syndrome (MDS), also referred to as a "bone marrow failure disorder" is a type of bone marrow disorder, in which the bone marrow does not produce enough healthy blood cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differ­entiation, and apoptosis. This syndrome usually affects the geriatric population and more often in older men than women. MD syndrome is characterized by specific chromosomal mutations in Janus Kinase gene, that include deletion of q arm in one or more chromosomes and complete the deletion of chromosome 5 or 7 and an extra copy of chromosome 8. MDS is diagnosed through several techniques including blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry, immunotherapy, cytogenetics, FISH, and PCR. The MDS International Foundation is a nonprofit health organization which provide psychological support as well as funding to patients for treatment of the disorder.

Market Dynamics

The global myelodysplastic syndrome (MDS) treatment market growth is driven by several factors such as the rising geriatric population, growing awareness, the emergence of novel therapeutics, government initiatives to provide target-specific treatments and favourable reimbursement policies.

Myelodysplastic syndrome is one of the most common malignant haematological diseases that occur at a rate of 4.8 cases for every 100,000 people. About 60,000 people in the U.S. live with MDS, and over 13,000 new cases are reported annually as per American Cancer Society data. The new cases diagnosed each year is increasing as the average age of the population increases. Patients may present with clinical manifestations such as anaemia, thrombocytopenia, and neutropenia.

The MDS treatment market is expected to grow significantly during the forecast period, owing to the increasing pipeline drugs, drug approvals and R&D investments in the development of novel drugs for myelodysplastic syndrome. For instance, in July 2020, the U.S. Food and Drug Administration approved Inqovi (decitabine and cedazuridine) tablets for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML). This is an important advancement in treatment options for patients with MDS, a type of blood cancer, who previously needed to visit a health care facility to receive intravenous therapy.

Also, in 2018, Lupin received approval for its Decitabine for injection, 50 mg/vial, Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Otsuka Pharmaceutical Co. Ltd's Dacogen for Injection, 50 mg/vial, single-dose vial.

However, the side effects associated with chemotherapy medications and high cost of therapeutics are expected to hamper the growth of the myelodysplastic syndrome treatment market.

Market Segment Analysis

Based on treatment type, the myelodysplastic syndrome (MDS) market is classified into chemotherapy, stem cell transplant, immune treatments, growth factors, and other treatments. Among these, the stem cell transplant (SCT) segment is expected to grow significantly over the forecast period. Stem cell transplantation offers a potentially beneficial therapy for the patients with myelodysplastic syndromes. There are two major types of SCT, one is allogeneic stem cell transplant and the other is an autologous stem cell transplant. For an allogeneic stem cell transplant, after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person, the donor. This is the type of transplant typically used for MDS. In an autologous stem cell transplant, the patients get back their own stem cells (which were removed before treatment). This type of transplant is not typically used for patients with MDS because the patient's bone marrow contains abnormal stem cells.

The chemotherapy segment is further segmented based on drug class such as hypomethylating agents, immunomodulatory drugs, and anti-anemics

MDS drugs are divided into the following therapeutic classes: hypomethylating agents, immunomodulatory drugs, and anti-anemics. Among these, the immunomodulatory drugs accounted for largets market share in 2019, due to growing adoption of therapeutics and lack of generic competition. Currently, Revlimid (lenalidomide) is the only one approved for treatment of low-risk MDS and myelodysplastic syndrome with isolated del(5q). Lenalidomide is considered an immunomodulatory agent. This means it is able to enhance the activity of immune cells and reduce inflammation. This slows the growth of abnormal bone marrow cells. In addition, it improves the way certain white blood cells work and is thought to slow the growth of new blood vessels that feed the MDS cells. Lenalidomide (Revlimid®) is approved for treating MDS patients with isolated del(5q) MDS subtyped who are transfusion dependent (still need blood transfusions) and have a low or intermediate-1 risk IPSS (International Prognostic Scoring System) score. Research studies are currently looking at how well lenalidomide works for patients with other MDS subtypes.

Hypomethylating agents such as Celgene's Vidaza and Otsuka's Dacogen are used as first-line treatment for patients with high-risk myelodysplastic syndrome. This segment is forecast to witness a steep fall in market share due to patent expirations of both the aforementioned drugs, which has led to the launch of several generics in the market.

In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability and access to novel treatments in major countries provides strong commercial opportunities to the market. Azacitidine is in a class of medicines called hypomethylating agents. Drugs in this class help prevent the growth of abnormal bone marrow stem cells. Azacitidine was the first medicine approved by the U.S. Food and Drug Administration (FDA) specifically to treat MDS. It is approved to treat both low- and high-risk patients with all subtypes of MDS. Decitabine is in a class of medicines called hypomethylating agents. Drugs in this class help prevent the growth of abnormal bone marrow stem cells. Decitabine, like azacitidine, is approved by the U.S. Food and Drug Administration (FDA) specifically to treat MDS. It is approved to treat both low- and high-risk patients with all subtypes of MDS.

The anticipated launch of Celgene's luspatercept and Amgen's Aranesp in 2019 are projected to significantly fuel the anti-anemics drug segment. Both are under investigation in late-stage clinical trials for treatment of myelodysplastic syndrome. Recent study outcomes have demonstrated that they successfully increased RBC count in the blood, thus reducing need for frequent blood transfusions. Luspatercept-aamt is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who have been failed an erythropoiesis stimulating agent (ESA) or are unlikely to respond to an ESA, and are requiring transfusions of 2 or more red blood cell (RBC) units over 8 weeks.

The U.S. Food and Drug Administration (FDA) has approved four drugs to treat MDS:

  • Azacitidine (Vidaza) for both low- and high-risk patients with all sub-types of MDS
  • Decitabine (Dacogen) for both low- and high-risk patients with all sub-types of MDS
  • Lenalidomide (Revlimid) for transfusion-dependent MDS patients with isolated del(5q) and with a low or intermediate-1 risk IPSS score
  • Luspatercept-aamt (REBLOZYL) for adult MDS patients with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), who have been failed an erythropoiesis stimulating agent (ESA) or are unlikely to respond to an ESA, and are requiring transfusions of 2 or more red blood cell (RBC) units over 8 weeks.
  • INQOVI (previously known as ASTX727) for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups including previously treated and untreated, de novo and secondary MDS including patients with refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts and CMML.

Market Geographical Analysis

North America region is dominating the global myelodysplastic syndrome treatment market accounted for the largest market share in 2019, owing to rising prevalence, high R&D investments on the development of the novel drugs, and the presence of advanced healthcare infrastructure. It is one of the most common malignant haematological diseases that affects five out of every 100,000 people in the U.S. annually. An estimated 60,000 people in the U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year.

In December 2019, Bristol-Myers Squibb and Acceleron Pharma announced that the FDA Advisory Committee would review Reblozyl (luspatercept-aamt) for use in patients with myelodysplastic syndrome.

Asia-Pacific is expected to experience lucrative growth in the global myelodysplastic syndrome treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions and a promising regulatory environment for new treatment. In September 2019, Astellas Pharma Inc. and FibroGen, Inc announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo® (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients. Roxadustat is also in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes.

Market Competitive Landscape

The myelodysplastic syndrome (MDS) treatment market is moderately competitive and consists of several major players. Some of the key players which are contributing to the growth of the market include AbbVie, Otsuka America Pharmaceutical Inc., Accord Healthcare Ltd., Novartis, Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Celgene Corporation, Sandoz, Inc., Dr. Reddy's Laboratories, Inc., among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myelodysplastic syndrome (MDS) treatment market globally. For instance,

  • In July 2020, Takeda Pharmaceutical Company announced the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).
  • In March 2020, Gilead Sciences, Inc. and Forty Seven, Inc. have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. Through the addition of Forty Seven's investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).
  • In June 2019, Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions..

Why Purchase the Report?

  • Visualize the composition of the myelodysplastic syndrome (MDS) treatment market segmentation by treatment type and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in myelodysplastic syndrome (MDS) treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of myelodysplastic syndrome (MDS) treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global myelodysplastic syndrome (MDS) treatment market report would provide an access to an approx. 53 market data table, 45 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Myelodysplastic Syndrome (MDS) Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myelodysplastic Syndrome (MDS) Treatment Market - Market Definition and Overview

3. Global Myelodysplastic Syndrome (MDS) Treatment Market - Executive Summary

  • 3.1. Market Snippet by Treatment Type
  • 3.2. Market snippet by End-User
  • 3.3. Market Snippet by Region

4. Global Myelodysplastic Syndrome (MDS) Treatment Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing R&D investments on the development of novel treatments for MDS
      • 4.1.1.2. Strong presence of pipeline drugs
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the medications
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myelodysplastic Syndrome (MDS) Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. COVID-19 Impact Analysis

6. Global Myelodysplastic Syndrome (MDS) Treatment Market - By Treatment Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
  • 6.3. Market Attractiveness Index, By Treatment Type Segment
    • 6.3.1. Stem Cell Transplant*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Immune Treatments
    • 6.3.3. Chemotherapy
      • 6.3.3.1. Hypomethylating Agents
      • 6.3.3.1.1. Azacitidine (Vidaza)
      • 6.3.3.1.2. Decitabine (Dacogen)
      • 6.3.3.2. Immunomodulatory Drugs
      • 6.3.3.2.1. Lenalidomide (Revlimid)
      • 6.3.3.2.2. Others
      • 6.3.3.3. Anti-anemics
      • 6.3.3.3.1. Luspatercept-aamt (REBLOZYL®)
      • 6.3.3.3.2. Others
      • 6.3.3.4. Others
      • 6.3.3.4.1. Cytarabine (Cytosar-U)
      • 6.3.3.4.2. Daunorubicin (Cerubidine)
      • 6.3.3.4.3. Idarubicin (Idamycin)
      • 6.3.3.4.4. INQOVI® (ASTX727)
    • 6.3.4. Growth factors
    • 6.3.5. Others

7. Global Myelodysplastic Syndrome (MDS) Treatment Market - By End-User

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 7.3. Market Attractiveness Index, By End-User Segment
    • 7.3.1. Hospitals*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others

8. Global Myelodysplastic Syndrome (MDS) Treatment Market - By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Italy
      • 8.3.5.5. Spain
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

9. Global Myelodysplastic Syndrome (MDS) Treatment Market - Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Global Myelodysplastic Syndrome (MDS) Treatment Market - Company Profiles

  • 10.1. Otsuka America Pharmaceutical Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. AbbVie
  • 10.3. Accord Healthcare Ltd.
  • 10.4. Novartis
  • 10.5. Bristol-Myers Squibb
  • 10.6. Takeda Pharmaceutical Company Limited
  • 10.7. Onconova Therapeutics
  • 10.8. Celgene Corporation
  • 10.9. Sandoz, Inc.
  • 10.10. Dr. Reddy's Laboratories, Inc.
  • 10.11. Mylan N.V.
  • 10.12. Pfizer, Inc.
  • 10.13. Argenx
  • 10.14. Jazz Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

11. Global Myelodysplastic Syndrome (MDS) Treatment Market - Premium Insights

12. Global Myelodysplastic Syndrome (MDS) Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us